Gilboa Therapeutics

Company Overview

Snapshot

Founded in October 2019 by Yaron Carmi, Gilboa Therapeutics operates with 1–10 employees. The company secured seed funding in September 2019 from NFX Capital, marking its first disclosed funding round.

Business overview

Gilboa Therapeutics is a preclinical-stage cancer immunotherapy company focused on developing next-generation cell therapies to improve outcomes for cancer patients. Its core product, SolidT, is designed to harness the patient's immune system for a highly specific and potent attack on tumors, with demonstrated complete eradication in animal models while preserving healthy tissue. The company's innovative platform technology aims to benefit patients with a range of solid and hematological tumors, offering an improved safety profile compared to existing cell therapy approaches within the Health Tech & Life Sciences sector.

Company Intelligence Q&A

What is Gilboa Therapeutics' primary focus?

Gilboa Therapeutics is a preclinical-stage cancer immunotherapy company dedicated to developing next-generation cell therapies for the treatment of cancer.

When was Gilboa Therapeutics founded?

Gilboa Therapeutics was founded in October 2019.

Who are the founders of Gilboa Therapeutics?

Yaron Carmi is a co-founder of Gilboa Therapeutics.

What is the key product developed by Gilboa Therapeutics?

Gilboa Therapeutics is focused on the development of SolidT, a next-generation cell therapy designed to harness the power of a patient's immune system to treat a wide range of cancers.

What is the current status of Gilboa Therapeutics?

Gilboa Therapeutics is currently non-active, having ceased to operate in July 2025.